Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia

In the last 10 years, oncology has been transformed by the development and broad availability of small molecule therapies for cancer. Compounds have been and are being developed to target nearly every known relevant component of the cell’s machinery. One class of compounds, the cyclin-dependent kinase (CDK) inhibitors, was originally conceived as an anticancer therapeutic based on the premise that as cancer is (in part) defined by loss of cell-cycle control, the interruption of cell cycle could arrest cancer growth.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research